Lucence declares the opening of molecular diagnostics lab in Singapore
Category: #health  By Paroma Bhattacharya  Date: 2019-02-01
  • share
  • Twitter
  • Google Plus
  • Facebook
  • LinkedIn

Lucence declares the opening of molecular diagnostics lab in Singapore

Lucence Diagnostics has reportedly made it to the headlines for having announced the opening of its new headquarters & molecular diagnostics laboratory in Singapore. As per sources familiar with the matter, the new facility spanning 10,000 square feet will help the firm penetrate into newer regional markets and meet the rising demand for its clinical services, in addition to upscaling its R&D operations.

Incidentally, the company has already expanded its business operations across San Francisco & Hong Kong and now plans to tap the Singapore market.

Renowned for inventing blood tests for rapid as well as non-invasive cancer detection, Lucence’s blood tests are officially available in around right countries, inclusive of Singapore, India, Philippines, Hong Kong, Malaysia, Thailand, Myanmar, and Vietnam. According to a press release by Lucence Diagnostics, alongside the opening of its new molecular diagnostics facility, the company has also launched its flagship blood test LiquidHALLMARK®, capable of detecting around 50 genetic mutations, 2 viruses, and 14 types of cancers. The LiquidHALLMARK® is the first blood test of its kind that detects both cancer-causing viruses and genetic mutations with an astounding 99.9% accuracy and delivers an intensive molecular profile of the tumor with just a single blood draw using AmpliMARK™ - the firm’s proprietary amplicon-based sequencing technology.

Dr. Tan Min-Han, Founder & CEO, Lucence Diagnostics, was reportedly quoted stating that the expanded molecular diagnostics laboratory is the first step ahead for the company to fulfill its vision of attaining zero avoidable cancer deaths via early detection and enhanced treatment choices. Min-Han affirmed that the company is indeed thrilled to have played a pivotal role in bettering the lives of thousands of patients across Asia with its portfolio of blood tests for cancer screening and treatment selection.

The opening at Singapore incidentally, was officiated by Dr. Koh Poh Koon, Senior Minister of State, Ministry of Trade & Industry.



About Author

Paroma Bhattacharya

Email: paroma.b@news.marketsizeforecasters.com   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Kerry Logistics JV with E-Services Group aims at e-commerce fulfilment
Kerry Logistics JV with E-Services Group aims at e-commerce fulfilment
By Paroma Bhattacharya

The companies will be combining their global supply chain facilities, technology platform and marketplace networks to offer cost-efficient solutions to e-retailers.

Drug combination could set norms for advanced kidney cancer treatment
Drug combination could set norms for advanced kidney cancer treatment
By Paroma Bhattacharya

Reporting the results from a phase 3 clinical trial, an investigator from Dana-Farber Cancer Institute revealed that the combination of two drugs could be a first-line, new standard treatment for patients that are suff...

IBM Watson collaborates with Broad Institute to explore genomics data
IBM Watson collaborates with Broad Institute to explore genomics data
By Paroma Bhattacharya

The initiative is expected enhance understanding of intrinsic possibility that individuals have for any specific disease.

IBM Watson Health, a cognitive healthcare ...